Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses the use of lenvatinib in the first line setting for the treatment of hepatocellular carcinoma. This was recorded at the 2917 Annual Meeting Annual Meeting in Chicago, IL.
Lenvatinib in the 1st line for uHCC treatment
